Ocular Therapeutix, Inc. ( OCUL) Bank of America Global Healthcare Conference 2026 May 12, 2026 6:40 PM EDT Ocular Therapeutics. Presenting for Ocular today and sitting up on stage with me is Dr.

We were pleased with Regeneron's performance to start 2026, highlighted by strong commercial execution across our key growth products, continued pipeline progress, a disciplined approach to capital ...

First quarter 2026 revenues increased 19% to $3.6 billion versus first quarter 2025Dupixent- global net sales (recorded by Sanofi) increased 33% to $4.9 billion EYLEA HD- U.S. net sales increased 52% ...

Background The standard of care for neovascular age-related macular degeneration (nAMD) is repeated intravitreal injection ...

Dupixent showed significant and clinically meaningful improvements in both esophageal distensibility as well as disease-related structural ...

Good baseline visual acuity retained in three-fourths of patients at 36 weeks with OTX-TKI ...

Amgen AMGN reported first-quarter adjusted earnings of $5.15 per share, which beat the Zacks Consensus Estimate of $4.73 per ...

April 29 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab beat Wall Street estimates for first-quarter revenue and profit on Wednesday, helped by strong demand ‌for its eczema drug, ...

Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Aflibercept 8 mg improved injection intervals in eyes ...

On April 2, 2026, Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration has approved an extension to the dosing intervals for EYLEA HD (aflibercept) patients with wet ...